Covetrus and MWI move toward a $3.5 billion merger: full analysis

Covetrus and MWI Animal Health are moving to combine two major pieces of the veterinary business stack: distribution and technology. In a definitive agreement announced February 18, 2026, Covetrus and MWI said they plan to merge into a combined animal health platform serving companion animal, equine, and production animal markets, with MWI valued at $3.5 billion in the transaction. (investor.cencora.com)

The structure of the deal helps explain why it matters beyond headline M&A activity. Cencora, MWI’s parent company, will receive $1.25 billion in cash, $800 million in preferred equity, and $1.45 billion in common equity, and will retain a 34.3% non-controlling stake in the merged company. Cencora has said the move lets it keep exposure to animal health while focusing more capital and attention on its broader growth priorities. The company also reaffirmed its fiscal 2026 guidance and said the transaction is not expected to close before the end of its fiscal year on September 30, 2026. (investor.cencora.com)

There’s also a longer arc here. Covetrus has spent years positioning itself as a technology-and-services company for veterinary practices, and it was taken private in 2022 by Clayton, Dubilier & Rice and TPG in a transaction valued at about $4 billion. MWI, by contrast, has been known for scale in animal health distribution and long-standing relationships across companion and production animal channels. The merger brings those models together at a time when veterinary practices are under pressure to improve workflow efficiency, manage inventory closely, and protect margins. (covetrus.com)

According to the companies, the combined business will pair MWI’s supply chain and distribution footprint with Covetrus’ software, pharmacy, and other tech-enabled services. In their announcement, executives argued the combination should broaden access to products and services, improve logistics, and create savings across the animal health ecosystem. Today’s Veterinary Business similarly described the transaction as one that could yield cost savings for practices by linking MWI’s supply chain capabilities with Covetrus’ pharmacy and practice-management offerings. (investor.cencora.com)

Public expert commentary appears limited so far, but early industry coverage has treated the merger as a significant consolidation event. AAHA’s Trends publication described it as another major shift in the veterinary distribution landscape, underscoring how closely practices now depend on a small number of large suppliers and service platforms. That framing aligns with the likely read from clinic leaders: this is not just a wholesaler deal, but a move toward deeper vertical integration across procurement, fulfillment, and practice operations. That last point is an inference based on the companies’ stated strategy and the assets being combined. (aaha.org)

Why it matters: For veterinary professionals, the upside is potential simplification. A more integrated vendor could make it easier to connect purchasing, inventory, pharmacy, and software workflows, especially for practices trying to reduce administrative friction or standardize across multiple sites. But the deal also raises practical questions about market concentration, negotiating leverage, service quality, and optionality for clinics that prefer to keep distribution and software relationships separate. In short, if the merger closes, it could reshape how practices buy products and how tightly those purchasing decisions are linked to the digital systems they use every day. (investor.cencora.com)

What to watch: The next milestones are regulatory review, closing conditions, and any clearer integration plans around branding, systems, field sales, and customer contracts. Practices will want to watch for specifics on whether ordering platforms, pharmacy services, and software products will be bundled more tightly, and whether the companies outline a timeline for operational changes after closing. For now, the clearest date on the calendar is Cencora’s statement that the deal is not expected to close before September 30, 2026. (investor.cencora.com)